Inclusion Criteria:~1. Outpatients from both sex~2. Age ≥ 50 years at screening~3. Menopause ≥ 2 years for
women~4. Dementia of Alzheimer's type, according to DSM IV criteria~5. Probable Alzheimer' disease according to
NINCDS-ADRDA criteria~6. MMSE ≥ 12 and ≤ 26 at baseline~7. CDR of 1 or 2 at baseline~8. Treated for a minimum
of 6 months with a stable dose of cholinesterase inhibitors (donepezil, rivastigmine or galantamine) at
baseline, and/or a stable dose of memantine for a minimum of 3 months at baseline, with no changes foreseen in
therapy throughout the study~9. Presence of a reliable caregiver~10. Patient, identified caregiver and, if
applicable, patient surrogate are able and willing to comply with study visits and procedures per protocol,
understand, sign, and date the written voluntary informed consent form at the screening visit prior to any
protocol-specific procedures performed~11. Affiliated to the French Social Security regimen~
